Loading
Bladder and Urothelial Cancer Treatments / HER2/EGFR in Cancer Research / Advanced Breast Cancer Therapies · Journal article
Frontiers in Pharmacology · August 17, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that systematically summarizes known mechanisms of resistance to antibody-drug conjugates in bladder cancer and discusses potential countermeasures. It does not present new empirical evidence or test a hypothesis; rather, it frames resistance as a complex, multifactorial process and calls for deeper investigation and development of predictive biomarkers.
Journal article. Patients with bladder cancer, specifically locally advanced or metastatic urothelial carcinoma treated with ADCs.
ADCs have demonstrated significant clinical benefit in locally advanced or metastatic urothelial carcinoma Resistance to ADCs in BC is driven by multiple tumor-intrinsic and tumor-extrinsic factors Potential strategies to overcome resistance include next-generation ADCs, combination therapies, and predictive biomarkers
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review identifies ADC resistance as a key limitation to durability of therapeutic efficacy and suggests that understanding BC-specific mechanisms may enable more precise and individualized treatment strategies. However, as a narrative synthesis without new trial data or validated predictive models, it provides context rather than actionable clinical evidence.
A narrative review summarizing mechanistic theories of ADC resistance in bladder cancer; raises questions about resistance pathways rather than testing them empirically.
This review identifies ADC resistance as a key limitation to durability of therapeutic efficacy and suggests that understanding BC-specific mechanisms may enable more precise and individualized treatment strategies. However, as a narrative synthesis without new trial data or validated predictive models, it provides context rather than actionable clinical evidence.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Antibody-drug conjugates (ADCs) have made important advances in the treatment of bladder cancer (BC) in recent years and have demonstrated significant clinical benefit in locally advanced or metastatic urothelial carcinoma (UC). However, the emergence of resistance remains a key factor limiting the durability of their therapeutic efficacy. Current evidence indicates that resistance to ADCs in BC is a complex process driven by multiple tumor-intrinsic and tumor-extrinsic factors. This review systematically summarizes the major mechanisms underlying ADC resistance in BC and outlines potential strategies to overcome it, including the development of next-generation ADCs, combination therapies, and predictive biomarkers. A deeper understanding of BC-specific mechanisms of ADC resistance will help promote the development of more precise and individualized ADC-based treatment strategies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.